公开(公告)号：IL176958D0

公开(公告)日：2006-12-10

申请号：IL17695806

申请日：2006-07-19

Applicant: MATTHEW WEISS ,  AMGEN INC ,  MICHELE POTASHMAN ,  TAE SEONG KIM ,  STEVEN BELLON ,  SHON BOOKER ,  YUAN CHENG ,  JOSEPH L KIM ,  ANDREW TASKER ,  NING XI ,  SHIMIN XU ,  JEAN CHRISTOPHE HARMANGE ,  GEORGE BORG ,  BRIAN L HODOUS ,  RUSSELL GRACEFFA ,  WILLIAM H BUCKNER ,  CRAIG E MASSE ,  DEBORAH CHOQUETTE ,  MATTHEW W MARTIN ,  JULIE GERMAIN ,  LUCIAN V DIPIETRO ,  STUART C CHAFFEE ,  JOHN L BUCHANAN ,  GREGORY J HABGOOD ,  DAVID C MCGOWAN ,  DOUGLAS A WHITTINGTON ,  DANIEL LA ,  VINOD F PATEL ,  JOSEPH J NUNES

IPC: C07D20100101 ,  C07D213/64 ,  C07D213/81 ,  C07D215/22 ,  C07D215/233 ,  C07D215/38 ,  C07D215/48 ,  C07D215/54 ,  C07D217/24 ,  C07D237/34 ,  C07D239/30 ,  C07D239/34 ,  C07D239/46 ,  C07D239/84 ,  C07D239/94 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

公开(公告)号：AU2010229147A1

公开(公告)日：2011-08-25

申请号：AU2010229147

申请日：2010-03-15

Applicant: SHENZHEN DONGYANGGUANG IND DEV CO LTD ,  NING XI

Inventor： NING XI

IPC: A01N37/12

Abstract: The present invention provides amino ester compounds, salts, and pharmaceutical formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

公开(公告)号：US09573953B2

公开(公告)日：2017-02-21

申请号：US14181670

申请日：2014-02-15

Applicant: Ning Xi

Inventor： Ning Xi

IPC: C07D487/04 ,  C07D471/04 ,  A61K31/444 ,  A61K45/06 ,  A61K31/519

CPC classification number: C07D487/04 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/519 ,  A61K45/06 ,  C07D471/04 ,  A61K2300/00

Abstract: The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Abstract translation: 本发明提供了可用于调节蛋白激酶活性的杂芳族衍生物及其药学上可接受的盐和制剂，特别是磷脂酰肌醇3-激酶（PI3激酶）和mTOR，以及调节细胞间和/或细胞内信号活动如增殖， 分化，凋亡，迁移和侵袭。 本发明还提供包含这些化合物的药学上可接受的组合物和使用该组合物治疗哺乳动物，特别是人类中过度增殖性疾病的方法。

公开(公告)号：US20130282174A1

公开(公告)日：2013-10-24

申请号：US13832284

申请日：2013-03-15

Applicant: Ning Xi ,  Jianguo Zhao ,  Bingtuan Gao ,  Jing Xu ,  Matt Mutka ,  Li Xiao

Inventor： Ning Xi ,  Jianguo Zhao ,  Bingtuan Gao ,  Jing Xu ,  Matt Mutka ,  Li Xiao

IPC: B25J9/16

CPC classification number: B25J9/1682 ,  B25J9/104 ,  Y10S901/01

Abstract: A jumping robot is provided. In another aspect, a jumping robot weighs less than 50 grams, jumps at least 20 cm high and has a maximum linear dimension of 10 cm. A further aspect provides a robot that employs an electromagnetic actuator that actuates at least two of: jumping, steering, self-righting, and/or mid-air orientation control.

Abstract translation: 提供跳跃机器人。 在另一方面，跳跃机器人重量小于50克，跳跃至少20厘米高，最大直线尺寸为10厘米。 另一方面提供了一种使用致动器的电磁致动器的机器人，其致动：跳跃，转向，自对准和/或空中取向控制中的至少两个。

公开(公告)号：US08476434B2

公开(公告)日：2013-07-02

申请号：US12952156

申请日：2010-11-22

Applicant: Stephanie D. Geuns-Meyer ,  Brian L. Hodous ,  Stuart C. Chaffee ,  Paul Tempest ,  Ning Xi ,  Phillip R. Olivieri ,  Joseph L. Kim ,  Steven Bellon ,  Xiaotian Zhu ,  Yuan Cheng ,  Brian K. Albrecht ,  Vinod F. Patel ,  Victor J. Cee ,  Karina Romero ,  Hanh Nho Nguyen ,  Holly L. Deak ,  Rebecca E. Johnson

Inventor： Stephanie D. Geuns-Meyer ,  Brian L. Hodous ,  Stuart C. Chaffee ,  Paul Tempest ,  Ning Xi ,  Phillip R. Olivieri ,  Joseph L. Kim ,  Steven Bellon ,  Xiaotian Zhu ,  Yuan Cheng ,  Brian K. Albrecht ,  Vinod F. Patel ,  Victor J. Cee ,  Karina Romero ,  Hanh Nho Nguyen ,  Holly L. Deak ,  Rebecca E. Johnson

IPC: C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  A61K31/4427 ,  A61K31/506 ,  A61K31/54 ,  A61P19/02 ,  A61P35/00

CPC classification number: C07D213/73 ,  C07D239/42 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D409/14 ,  C07D413/14 ,  C07D471/04

Abstract: The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, H1-5 and R1-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other proliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.

Abstract translation: 本发明涉及具有通式I的化合物，其中A，B，D，E，G，H1-5和R1-4在本文中定义，以及能够调节各种蛋白激酶受体酶的合成中间体， 从而影响与这些激酶的活性相关的各种疾病状态和状况。 例如，化合物能够调节激酶，从而影响血管发生过程并治疗血管生成相关疾病和其它增殖性疾病，包括癌症和炎症。 本发明还包括药物组合物，包括该化合物，以及治疗与蛋白激酶活性有关的疾病状态的方法。

公开(公告)号：US08426585B2

公开(公告)日：2013-04-23

申请号：US13587936

申请日：2012-08-17

Applicant: Ning Xi

Inventor： Ning Xi

IPC: A61P35/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04

CPC classification number: A61K31/437 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D491/107 ,  C07D493/10 ,  C07D495/04 ,  C07D498/04 ,  C07D519/00

Abstract: The present invention provides novel compounds useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Abstract translation: 本发明提供了可用于调节蛋白酪氨酸激酶活性和调节细胞间和/或细胞内信号传导的新化合物。 本发明还提供包含这些化合物的药学上可接受的组合物和使用该组合物治疗哺乳动物，特别是人类中过度增殖性疾病的方法。

公开(公告)号：US20120315247A1

公开(公告)日：2012-12-13

申请号：US13587936

申请日：2012-08-17

Applicant: Ning Xi

Inventor： Ning Xi

IPC: A61K31/4709 ,  C07D401/12 ,  A61K31/704 ,  A61K31/664 ,  A61K31/573 ,  A61K31/7048 ,  A61K31/513 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K38/21 ,  A61K31/4745 ,  A61K39/395 ,  A61K31/4995 ,  A61P35/00 ,  A61P9/10 ,  A61P35/04 ,  C12N9/99 ,  C07D401/14

CPC classification number: A61K31/437 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D491/107 ,  C07D493/10 ,  C07D495/04 ,  C07D498/04 ,  C07D519/00

Abstract: The present invention provides novel compounds useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Abstract translation: 本发明提供了可用于调节蛋白酪氨酸激酶活性和调节细胞间和/或细胞内信号传导的新化合物。 本发明还提供包含这些化合物的药学上可接受的组合物和使用该组合物治疗哺乳动物，特别是人类中过度增殖性疾病的方法。

公开(公告)号：US08232294B2

公开(公告)日：2012-07-31

申请号：US12728153

申请日：2010-03-19

Applicant: Ning Xi

Inventor： Ning Xi

IPC: C07D215/38 ,  A61K31/04

CPC classification number: C07D215/20 ,  A61K31/4709 ,  A61K31/573 ,  A61K31/661 ,  A61K31/704 ,  A61K31/708 ,  A61K39/395 ,  A61K45/06 ,  C07D209/54 ,  C07D215/22 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07K16/18 ,  A61K2300/00

Abstract: The present invention provides amino ester compounds, salts, and pharmaceutical formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Abstract translation: 本发明提供用于调节蛋白酪氨酸激酶活性以及调节细胞间和/或细胞内信号传导的氨基酯化合物，其盐和药物制剂。 本发明还提供包含这些化合物的药学上可接受的组合物和使用该组合物治疗哺乳动物，特别是人类中过度增殖性疾病的方法。

公开(公告)号：US20120148531A1

公开(公告)日：2012-06-14

申请号：US13309488

申请日：2011-12-01

Applicant: Brian K. ALBRECHT ,  David Bauer ,  Steven Bellon ,  Christiane M. Bode ,  Shon Booker ,  Alessandro Boezio ,  Deborah Choquette ,  Derin D'Amico ,  Jean-Christophe Harmange ,  Satoko Hirai ,  Randall W. Hungate ,  Tae-Seong Kim ,  Richard T. Lewis ,  Longbin Liu ,  Julia Lohman ,  Mark H. Norman ,  Michele Potashman ,  Aaron C. Siegmund ,  Stephanie Springer ,  Markian Stec ,  Ning Xi ,  Kevin Yang

Inventor： Brian K. ALBRECHT ,  David Bauer ,  Steven Bellon ,  Christiane M. Bode ,  Shon Booker ,  Alessandro Boezio ,  Deborah Choquette ,  Derin D'Amico ,  Jean-Christophe Harmange ,  Satoko Hirai ,  Randall W. Hungate ,  Tae-Seong Kim ,  Richard T. Lewis ,  Longbin Liu ,  Julia Lohman ,  Mark H. Norman ,  Michele Potashman ,  Aaron C. Siegmund ,  Stephanie Springer ,  Markian Stec ,  Ning Xi ,  Kevin Yang

IPC: A61K31/5025 ,  A61K31/5377 ,  A61K38/21 ,  A61P35/00 ,  A61P35/04 ,  C07D487/04 ,  A61K31/538

CPC classification number: A61K31/538 ,  A61K31/437 ,  A61K31/497 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/52 ,  A61K31/5377 ,  A61K45/06 ,  C07D403/12 ,  C07D471/04 ,  C07D473/34 ,  C07D487/04 ,  C07D493/04 ,  C07D495/04 ,  C07D498/04 ,  C07D519/00

Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Abstract translation: 所选化合物对于预防和治疗诸如HGF介导的疾病等疾病是有效的。 本发明包括新颖的化合物，类似物，前药和药学上可接受的盐，用于预防和治疗疾病和其它疾病或涉及癌症等的病症的药物组合物和方法。 本发明还涉及制备这些化合物的方法以及在这些方法中有用的中间体。

公开(公告)号：US20120065185A1

公开(公告)日：2012-03-15

申请号：US13297213

申请日：2011-11-15

Applicant: Guoqing CHEN ,  Jeffrey Adams ,  Jean Bemis ,  Shon Booker ,  Guolin Cai ,  Lucian Di Pietro ,  Celia Dominguez ,  Daniel Elbaum ,  Julie Germain ,  Stephanie Geuns-Meyer ,  Michael Handley ,  Qi Huang ,  Joseph L. Kim ,  Tae-Seong Kim ,  Alexander Kiselyov ,  Xiaohu Ouyang ,  Vinod F. Patel ,  Leon M. Smith ,  Markian Stec ,  Andrew Tasker ,  Ning Xi ,  Shimin Xu ,  Chester Chenguang Yuan ,  Michael Croghan

Inventor： Guoqing CHEN ,  Jeffrey Adams ,  Jean Bemis ,  Shon Booker ,  Guolin Cai ,  Lucian Di Pietro ,  Celia Dominguez ,  Daniel Elbaum ,  Julie Germain ,  Stephanie Geuns-Meyer ,  Michael Handley ,  Qi Huang ,  Joseph L. Kim ,  Tae-Seong Kim ,  Alexander Kiselyov ,  Xiaohu Ouyang ,  Vinod F. Patel ,  Leon M. Smith ,  Markian Stec ,  Andrew Tasker ,  Ning Xi ,  Shimin Xu ,  Chester Chenguang Yuan ,  Michael Croghan

IPC: A61K31/4436 ,  A61K31/4709 ,  A61K31/4725 ,  A61P3/00 ,  A61P7/00 ,  A61P35/00 ,  A61P31/00 ,  A61K31/444 ,  A61K31/5377

CPC classification number: C07D213/82 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/538 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/00 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

Abstract translation: 所选择的杂环化合物对于预防和治疗诸如血管生成介导的疾病等疾病是有效的。 本发明包括新型化合物，类似物，前药及其药学上可接受的衍生物，用于预防和治疗疾病和其它疾病或涉及癌症等的病症的药物组合物和方法。